Rainbow Coral visits genome-mapping facility in Houston
Published on January 22, 2013 at 6:05 AM
Since the new year began, Rainbow Coral Corp. (OTCBB: RBCC) has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Company's executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner.
“Knowing specifics about an individual's genetic make-up can greatly assist a patient's doctor in determining correct doses of medications as well as ruling out medications that could prove harmful”
New healthcare innovations related to the human genome represent a target-rich area of interest for RBCC. The Texas company currently being reviewed performs tests to identify genetic markers in patients that can potentially boost or nullify the effects of certain medications.
Such testing could dramatically change the way medications are prescribed, potentially fostering a significant reduction in global health care costs.
"Knowing specifics about an individual's genetic make-up can greatly assist a patient's doctor in determining correct doses of medications as well as ruling out medications that could prove harmful," said RBCC CEO Patrick Brown. "Genome mapping opens up a host of new possibilities for doctors and patients alike, and we're very interested in the technology's economic potential."
As the company searches for its next partner, RBCC's biotech subsidiary Rainbow Biosciences remains close to a joint venture deal with Amarantus Bioscience, makers of exciting new diagnostic tools and therapies for neurological diseases such as Parkinson's.
Amarantus recently announced highly promising results in new animal trials of its forthcoming Parkinson's therapeutic.
Source: Rainbow BioSciences